NCT00259337View on ClinicalTrials.gov

Immunogenicity and Safety of Pentaxim™ in an Indian Population

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2008

Conditions
DiphtheriaTetanusPolioPertussisHaemophilus Infections
Interventions
BIOLOGICAL

Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine

0.5 mL, IM

Trial Locations (1)

Unknown

New Delhi

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00259337 - Immunogenicity and Safety of Pentaxim™ in an Indian Population | Biotech Hunter | Biotech Hunter